Agency U.S. Food and Drug Administration (FDA) approved the use of "vaccines" against prostate cancer. A vaccine, designed to activate the body's immune system to ward off cancer in the body.
Doses of this vaccine is made individually for each patient. Experts say, the therapy is not intended to replace, but in addition to the handling of existing prostate cancer. The vaccine is aimed at an advanced stage cancer patients that cancer has spread to other parts of the body and does not respond to standard hormone therapy.
Clinical trials show that this new vaccine could prolong the life expectancy of patients with up to four months, longer than chemotherapy, which extend the age of three months. Unfortunately the price of this vaccine is still expensive, which is about 93 million rupiah per patient.
"This is the first immunotherapy approval. It is estimated that in 50-10 years' time will be the primary therapy immunotherapy cancer treatment," said Dr. Phil Kantoff, cancer specialists from Dana-Farber Cancer Institute.
For years, experts continue to explore the possibility of the human immune system against tumors. One that is promising is to inhibit melanoma vaccine trial, an advanced stage of tumor development form into cancer.
Prostate cancer is very common in the U.S. experienced man. Increasing age also increases the risk of prostate cancer. It is estimated that at the age of 50 years, one of four men have cancer cells in his prostate gland. There were several methods of controlling prostate cancer, doctors usually will recommend a combination of surgery followed by radiation therapy and hormones.
0 comments:
Post a Comment